Navigation Links
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Date:8/19/2007

programs for the inhaler include; a multi-product development and licensing agreement with Novartis for its proprietary respiratory compounds, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense in co-development with the University of Pittsburgh. In addition, MicroDose has undisclosed collaborations ongoing with major pharmaceutical partners in the respiratory market segment.

MicroDose's second drug delivery platform, PolyCap(TM), is a fixed-dose-combination oral dosage technology, which allows two or more drugs to be combined in a single capsule, but separated by a physical barrier. Internal development programs utlilizing PolyCap(TM) are underway in the areas of diabetes, hypertension and hyperlipidaemia. PolyCap(TM) is also available for license to pharmaceutical partners for their combination product needs.

For further information please visit MicroDose's website at http://www.microdose-tech.com

About Diabetes

Diabetes is a chronic health condition where the body is unable to produce or adequately use insulin. Diabetes is broadly grouped into two types -- Type I and Type 2. Type 2 diabetics make up approximately 90% of all diabetics and the incidence of Type 2 diabetes is growing rapidly. According to the World Health Organization, diabetes is reaching epidemic proportions. Approximately 194 million people worldwide suffer from the disease, and it is estimated that the number of people with diabetes will more than double by 2030. Predictions are that one in three children in the U.S. born five years ago will develop diabetes. Direct healthcare costs may be as much as $286 billion worldwide. It is widely accepted that early intervention for Type 2 diabetics by treatment with insulin improves outcomes. However, as Type 2 diabetics are reluctant to inject insulin the introduction of non-invasive insulin delivery formats, such as inhalab
'/>"/>

SOURCE MicroDose Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... Aug. 22, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... launch and availability of ONSOLIS (fentanyl buccal soluble film) ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is approved in ... be marketed as BREAKYL) for the management of breakthrough ...
... the Food and Drug Administration (FDA) approved Seattle Genetics, ... – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). ... approved for Hodgkin lymphoma patients after failure of a ... ALCL patients after failure of at least one multi-agent ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977 2
(Date:9/20/2014)... (PRWEB) September 20, 2014 The festival season ... busy selling its newly released luxurious cocktail dresses . ... company has recently decided to launch a new promotion for ... is offered with a discounted price, from 20 to 71 ... a wide range of choices. They are provided in many ...
(Date:9/20/2014)... September 20, 2014 New PharmaPoint ... Market Analysis to 2023?. The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ...
(Date:9/20/2014)... the popular online supplier of wedding dresses and special ... collection of cocktail gowns. This afternoon, the company announced ... outfits; it intends to expand its online market in ... cocktail dresses in the company’s online store. ... experience in the industry of women’s special occasion dresses. ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The excitement is building ... Mount Airy, North Carolina. This year the Surry Arts Council ... people from around the country who are still fans of the ... is a sitcom that aired on CBS from 1960 through 1968. ... show in American television history. Mount Airy, North Carolina is ...
(Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2
... and high-school students who bully their classmates are more likely ... marijuana, a new study found. Researchers found that bullies ... were more likely to use substances than were victims ... behavior may be related to another," said Kisha Radliff, lead ...
... (March 5, 2012) Chinese Minister of Health, Dr. Zhu ... researchers from across the U.S. and China with the goal ... and creating deeper ties to fast-track cancer research. The ... renowned cancer experts, designed to develop a framework for future ...
... -- Vitamin E may stimulate cells that result in ... by Shu Takeda of Keio University in Tokyo said ... vitamin E supplements. The researchers explain that maintaining ... (osteoclasts) keeps bones strong. Although prior studies had suggested ...
... , MONDAY, March 5 (HealthDay News) -- Babies ... greater risk of developing asthma when compared with children born ... to infants born between the 34th and 37th week of ... an asthma diagnosis by the age of 8 years, despite ...
... March 2012: Each year over 4.3 million people ... yet many of these deaths might have been prevented ... smoking cessation, weight loss, improved diets and increased ... interventions will be presented, together with cutting-edge research on ...
... Fla. Researchers have identified a gene that causes adult-onset ... twist involuntarily. The discovery by a team from the Jacksonville, ... Health Sciences Center sheds light on a movement disorder that ... Annals of Neurology . In 1990, ...
Cached Medicine News:Health News:School bullies more likely to be substance users, study finds 2Health News:School bullies more likely to be substance users, study finds 3Health News:Chinese Minister of Health to hold US meeting to improve cancer research collaboration 2Health News:Mouse Study Suggests Vitamin E May Weaken Bones 2Health News:Late Preemie Birth May Be Linked to Higher Asthma Risk 2Health News:EuroPRevent2012, the premier international forum for preventive cardiology 2Health News:EuroPRevent2012, the premier international forum for preventive cardiology 3Health News:EuroPRevent2012, the premier international forum for preventive cardiology 4Health News:EuroPRevent2012, the premier international forum for preventive cardiology 5Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 3
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: